Patents Examined by Ilia I Ouspenski
-
Patent number: 10273306Abstract: The invention relates to a specific antibody directed against, for use for treating graft versus host disease.Type: GrantFiled: June 2, 2017Date of Patent: April 30, 2019Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Centre Leon Berard, Université d' Aix-MarseilleInventors: Gilles Marodon, Daniel Olive, Christine Menetrier-Caux
-
Patent number: 10273301Abstract: The present invention relates to novel antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of making and using same. Methods of use include methods of treatment of cancer, including leukemias, lymphomas, solid tumors and melanomas.Type: GrantFiled: December 22, 2014Date of Patent: April 30, 2019Assignee: JANSSEN PHARMACEUTICA NVInventors: Linda Snyder, Gordon Powers
-
Patent number: 10266595Abstract: The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.Type: GrantFiled: December 7, 2018Date of Patent: April 23, 2019Assignee: Bristol-Myers Squibb CompanyInventors: John P. Cogswell, Stacie M. Goldberg, Ashok K. Gupta, Maria Jure-Kunkel, Xi-Tao Wang, Jon M. Wigginton
-
Patent number: 10266594Abstract: The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.Type: GrantFiled: December 7, 2018Date of Patent: April 23, 2019Assignee: Bristol-Myers Squibb CompanyInventors: John P. Cogswell, Stacie M. Goldberg, Ashok K. Gupta, Maria Jure-Kunkel, Xi-Tao Wang, Jon M. Wigginton
-
Patent number: 10259849Abstract: The present invention relates to B7-H4-specific compositions and methods of use thereof.Type: GrantFiled: January 28, 2016Date of Patent: April 16, 2019Assignee: The Trustees of the University of PennsylvaniaInventors: Nathalie Scholler, Denarda Dangaj, Aizhi Zhao, Daniel J. Powell
-
Patent number: 10253097Abstract: An antibody capable of potentiating immune responses and modifying existing states of immune responsiveness is described, as is the sequence of the antibody. Also described are compositions containing the antibody, as well as methods for using the antibody and the compositions to enhance immune responses, to enhance DC function, to modify an existing state of immune responsiveness, to immunize individuals, or to treat or inhibit conditions such as allergic asthma.Type: GrantFiled: January 6, 2016Date of Patent: April 9, 2019Assignee: Mayo Foundation for Medical Education and ResearchInventors: Larry R. Pease, Virginia Van Keulen, Bogolub Ciric
-
Patent number: 10251945Abstract: The present invention provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies) that bind to human Inducible T Cell COStimulator (ICOS) and exhibit therapeutically desirable functional properties, e.g., the ability to stimulate human ICOS activity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells, and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the antibodies of the invention are also provided. The antibodies of the invention can be used, for example, as an agonist to stimulate or enhance an immune response in a subject, e.g., antigen-specific T cell responses against a tumor or viral antigen. The antibodies of the invention can also be used in combination with other antibodies (e.g., PD-1, PD-L1, and/or CTLA-4 antibodies) to treat, for example, cancer.Type: GrantFiled: November 21, 2018Date of Patent: April 9, 2019Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: John J. Engelhardt, Mark J. Selby, Alan J. Korman, Mary Diane Feingersh, Brenda L. Stevens
-
Patent number: 10239942Abstract: Antibodies that bind to programmed cell death protein 1 (PD-1), compositions comprising such antibodies, and methods of making and using such antibodies are disclosed.Type: GrantFiled: December 19, 2015Date of Patent: March 26, 2019Assignee: PD-1 Acquisition Group, LLCInventors: Najmia Amirina, Hareesh Chamarthi, Maria Isabel Chiu, Daniel Doty, Bin Feng, Aleksander Jonca, Thomas McQuade, Anhco Nguyen, Sheila Ranganath, Hans Albert Felix Scheuplein, Vikki A. Spaulding, Lei Wang, Jennifer Watkins-Yoon, Sri Sahitya Vadde
-
Patent number: 10233242Abstract: A method of treating, preventing, or delaying the progression of Type 1 diabetes mellitus autoimmunity by administering an effective amount of a cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) molecule is provided herewith. The CTLA4 molecule may be a fusion protein of a CTLA4 extracellular region and an immunoglobulin, such as abatacept.Type: GrantFiled: December 19, 2014Date of Patent: March 19, 2019Assignee: DMNOMOREInventor: Tihamer Orban
-
Patent number: 10214585Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.Type: GrantFiled: September 10, 2015Date of Patent: February 26, 2019Assignee: Yeda Research and Development Co., Ltd.Inventors: Michal Eisenbach-Schwartz, Kuti Baruch, Neta Rosenzweig
-
Patent number: 10214586Abstract: The present invention relates to antibodies that bind human programmed cell death 1 ligand 1 (PD-L1), and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and other cancer therapeutics.Type: GrantFiled: August 18, 2016Date of Patent: February 26, 2019Assignee: Eli Lilly and CompanyInventors: Dale Lincoln Ludwig, Marshall Davenport Snavely, Yiwen Li, Juqun Shen, Vera Molkenthin
-
Patent number: 10208119Abstract: Provided are anti-PD-L1 antibodies or fragments thereof. The antibodies or fragments thereof specifically bind to the immunoglobulin C domain of the PD-L1 protein. In various example, the antibodies or fragments thereof include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and infectious diseases are also provided.Type: GrantFiled: August 9, 2018Date of Patent: February 19, 2019Assignee: I-MABInventors: Lei Fang, Zhengyi Wang, Bingshi Guo, Jingwu Zang
-
Patent number: 10208115Abstract: The present invention relates to amino acid sequences that block the interaction between (a target on) an antigen presenting cell (APC) and (a target on) a T-cell. More particularly, the present invention relates to amino acid sequences that are directed against (as defined herein) a target on an APC (also referred to herein as “APC target”) or a target on a T-cell (also referred to herein as “T-cell target”). The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.Type: GrantFiled: February 23, 2016Date of Patent: February 19, 2019Assignee: Ablynx N.V.Inventors: Guy Hermans, Peter Verheesen, Edward Dolk, Hendricus Renerus Jacobus Mattheus Hoogenboom, Michael John Scott Saunders, Hans De Haard, Renee de Bruin
-
Patent number: 10202453Abstract: There is disclosed compositions and methods relating to or derived from anti-CTLA4 antibodies. More specifically, there is disclosed fully human antibodies that bind CTLA4, CTLA4-antibody binding fragments and derivatives of such antibodies, and CTLA4-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring either stimulation of immune responses or suppression.Type: GrantFiled: February 12, 2016Date of Patent: February 12, 2019Assignee: Sorrento Therapeutics, Inc.Inventors: John Dixon Gray, Heyue Zhou
-
Patent number: 10196450Abstract: Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.Type: GrantFiled: May 26, 2017Date of Patent: February 5, 2019Assignee: Board of Regents, The University of Texas SystemInventors: Yong-Jun Liu, Kui Shin Voo, Laura Bover, Naoya Tsurushita, J. Yun Tso, Shankar Kumar
-
Patent number: 10196452Abstract: The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.Type: GrantFiled: November 8, 2017Date of Patent: February 5, 2019Assignees: Pfizer Inc., Bristol-Myers Squibb CompanyInventors: Jing Min, Yanli Wu, Rory F. Finn, Barrett R. Thiele, Wei Liao, Ronald P. Gladue, Arvind Rajpal, Timothy J. Paradis, Peter Brams, Brigitte Devaux, Yi Wu, Kristopher Toy, Heidi N. Leblanc, Haichun Huang
-
Patent number: 10196445Abstract: The present invention provides anti-CTLA-4 antibodies having enhanced ADCC activity, and their use in treating cancer. In one embodiment, the anti-CTLA-4 antibody is ipilimumab, and ADCC activity is enhanced by introducing G236A, S239D, A330L and I332E mutations (“GASDALIE”) into the Fc region of the heavy chain constant domain.Type: GrantFiled: March 16, 2016Date of Patent: February 5, 2019Assignee: Bristol-Myers Squibb CompanyInventors: John J. Engelhardt, Alan J. Korman, Mark J. Selby
-
Patent number: 10174113Abstract: The invention provides a method of treating a melanoma comprising (i) identifying a patient having a PD-L1-negative melanoma and (ii) administering to the patient a combination of an anti-PD-1 antibody or an antigen-binding portion thereof and an anti-CTLA-4 antibody or an antigen-binding portion thereof. The methods of the invention can extend progression-free survival for over 8 months and/or reduces the tumor size at least about 10%, about 20%, about 30%, about 40%, or about 50% compared to the tumor size prior to the administration.Type: GrantFiled: April 28, 2016Date of Patent: January 8, 2019Assignee: Bristol-Myers Squibb CompanyInventor: Arvin Yang
-
Patent number: 10167336Abstract: This document provides methods and materials involved in treating cancer. For example, methods and materials for identifying a mammal as having an elevated level of PD-1+/CD11ahigh CD8 T cells having the potential to exert anti-cancer effects are provided. In addition, methods and materials for identifying a mammal as having an elevated level of PD-1+/CD11ahigh CD8 T cells and administering a PD-1 inhibitor to such a mammal are provided.Type: GrantFiled: February 26, 2016Date of Patent: January 1, 2019Assignee: Mayo Foundation for Medical Education and ResearchInventors: Haidong Dong, Eugene D. Kwon, Svetomir N. Markovic, Christopher J. Krco
-
Patent number: 10167337Abstract: Agonists to ICOS in combination with a blocking agent to a T cell inhibitory receptor (e.g., CTLA-4, PD-1, etc.) are demonstrated herein to be useful for the treatment of tumors.Type: GrantFiled: May 4, 2018Date of Patent: January 1, 2019Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: James Allison, Padmanee Sharma, Sergio A. Quezada, Tihui Fu